Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer
Abstract
Purpose: TP53 missense mutations may help to identify prostate cancer with lethal potential. Here, we preanalytically, analytically, and clinically validated a robust IHC assay to detect subclonal and focal TP53 missense mutations in prostate cancer.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 14, 2017
- Source ID
- 10.1158/1078-0432.ccr-17-0257
Entities
People
- Angelo M De Marzo
- Ashley E. Ross
- Edward M. Schaeffer
- Fawaz Almutairi
- Gaurav Rajoria
- George J. Netto
- Kasra Yousefi
- Liana B. Guedes
- Michael C. Haffner
- Rajni Sharma
- Roberto Zoino
- Szczepan Klimek
- Tamara L Lotan
- William B Isaacs
- Zach Liu
Organizations
- Congressionally Directed Medical Research Programs
- Johns Hopkins University
- National Institutes of Health